NRG Therapeutics is passionate about bringing new medicines and hope to the growing number of people worldwide living with debilitating neurodegenerative disorders.
An innovative, clinical stage neuroscience company building a pipeline of disease-modifying drug candidates, NRG is focused on therapeutic approaches that will rectify mitochondrial function and slow or halt the progression of neurodegenerative diseases such as amyotrophic lateral sclerosis, ALS (also known as motor neuron disease, MND) and Parkinson’s.
The company benefits from the drug discovery and neuroscience expertise and insights, and biotech experience of its founders, leadership team, investors, advisors, and collaborators.
NRG Therapeutics is leveraging breakthrough science in mitochondrial biology and disease mechanisms to develop novel medicines to treat neurodegenerative disorders.
The company’s pipeline of first-in-class, CNS-penetrant, oral small molecules is based on inhibiting the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action.
Our lead drug candidate NRG5051 commenced a first-in-human clinical trial in 2026.
